When evaluating Tiziana Life Sciences (TLSA) as an investment or assessing its technological approach, several inherent disadvantages and risks must be considered. As a clinical-stage biopharmaceutical firm, the company generates no commercial product sales, leading to ongoing financial losses, reliance on external equity financings, and potential shareholder dilution. Additionally, early-stage drug development carries high scientific risk, as pipeline candidates like foralumab must navigate lengthy, expensive clinical trials where failure to meet primary endpoints can severely impact company valuations.